HSBC Holdings
CPRX

HSBC Holdings’s Catalyst Pharmaceutical CPRX Stock Holding History

HSBC Holdings’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,629
Closed -$826K – 2981
2026
Q1 		$826K Sell
33,629
-24,300
-42% -$579K ﹤0.01% 1967
2025
Q4 		$1.36M Buy
57,929
+27,739
+92% +$618K ﹤0.01% 1762
2025
Q3 		$595K Sell
30,190
-21,632
-42% -$445K ﹤0.01% 2016
2025
Q2 		$1.12M Buy
51,822
+16,859
+48% +$398K ﹤0.01% 1741
2025
Q1 		$841K Sell
34,963
-1,374
-4% -$30.9K ﹤0.01% 1826
2024
Q4 		$764K Buy
36,337
+14,269
+65% +$307K ﹤0.01% 1947
2024
Q3 		$434K Sell
22,068
-10,834
-33% -$201K ﹤0.01% 2094
2024
Q2 		$504K Buy
32,902
+20,543
+166% +$320K ﹤0.01% 1958
2024
Q1 		$197K Buy
+12,359
New +$186K ﹤0.01% 2689
2023
Q1 		– Sell
-20,969
Closed -$385K – 2742
2022
Q4 		$385K Buy
20,969
+3,013
+17% +$46.4K ﹤0.01% 2404
2022
Q3 		$232K Buy
+17,956
New +$213K ﹤0.01% 2554

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HSBC Holdings's CPRX Position: Q2 2026 in Review

HSBC Holdings sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 33,629 shares — an estimated $826K sold.

HSBC Holdings first reported a position in CPRX in Q3 2022 and held it in 11 quarters. The position peaked at $1.36M in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • HSBC Holdings reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • HSBC Holdings sold 33,629 Catalyst Pharmaceutical shares in Q2 2026, an estimated $826K.
  • HSBC Holdings first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 11 quarters.
  • HSBC Holdings's Catalyst Pharmaceutical position peaked at $1.36M in Q4 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.